Docetaxel, Thalidomide, Prednisone, and Bevacizumab to Treat Metastatic Prostate Cancer

NCT00089609 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

73

Enrollment

NIH

Sponsor class

Conditions

Prostatic Neoplasms

Interventions

DRUG: Docetaxel
DRUG: Thalidomide
DRUG: Prednisone
BIOLOGICAL: bevacizumab
GENETIC: polymorphism analysis
OTHER: immunoenzyme technique
OTHER: laboratory biomarker analysis
OTHER: pharmacological study

Sponsor

National Cancer Institute (NCI)